Hansa Biopharma: Imlifidase confirms strong Kidney outcome in the US study - Redeye

The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserves a high eGFR level. Hansa does now expect to submit Imlifidase for auS approval in late 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1128848/hansa-biopharma-imlifidase-confirms-strong-kidney-outcome-in-the-us-study?utm_source=finwire&utm_medium=RSS